Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1004 vs Chemotherapy +/- Sintilimab in Advanced NSCLC with EGFR Exon 20 Insertion
NCT06281964Phase 3Enrolling by invitation
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jun 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Dec 2023; status: enrolling by invitation.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06281964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281964.